Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$13.99 USD
-0.27 (-1.89%)
Updated Aug 1, 2025 04:00 PM ET
Pre-Market: $13.99 0.00 (0.00%) 9:12 AM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About Dividend Yield (TTM)
Seres Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
MCRB 13.99 -0.27(-1.89%)
Will MCRB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MCRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MCRB
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade
MCRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround
After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)
Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now
Other News for MCRB
Seres???Therapeutics: Speculative Gem Backed By SER???155 FDA Breakthrough
Seres Therapeutics announces leadership transition
Seres Therapeutics (MCRB) Announces Transition in Executive Leadership | MCRB Stock News
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on ...
Seres Therapeutics Announces Leadership Transition | MCRB Stock News